Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Lenvatinib
Related studies linked through entity extraction aliases.
Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension
- Status
- COMPLETED
- Phase
- PHASE3
Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- NA
Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)
- Status
- UNKNOWN
- Phase
- PHASE2
Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis
- Status
- UNKNOWN
- Phase
- PHASE2
Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- NA
Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- Status
- RECRUITING
- Phase
- PHASE2
An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2